litlas
Log inCreate account

Filip Van den Bosch

Active 1999–2025

132
Papers
22,809
Citations
76
h-index
121
i10-index

Citations

Citations per year for Filip Van den Bosch1974: 1 citations1986: 2 citations1987: 1 citations1988: 2 citations1999: 2 citations2000: 3 citations2001: 16 citations2002: 54 citations2003: 43 citations2004: 67 citations2005: 85 citations2006: 47 citations2007: 43 citations2008: 39 citations2009: 54 citations2010: 64 citations2011: 110 citations2012: 89 citations2013: 80 citations2014: 86 citations2015: 88 citations2016: 102 citations2017: 136 citations2018: 174 citations2019: 751 citations2020: 920 citations2021: 877 citations2022: 724 citations2023: 549 citations2024: 1,008 citations2025: 432 citations2026: 6 citations1975–1985: no citations, so these years are not shown1989–1998: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,359 citing papers, 15.1% of this breakdownUnited Kingdom: 757 citing papers, 8.4% of this breakdownGermany: 694 citing papers, 7.7% of this breakdownNetherlands: 523 citing papers, 5.8% of this breakdownItaly: 496 citing papers, 5.5% of this breakdownCanada: 490 citing papers, 5.4% of this breakdownFrance: 479 citing papers, 5.3% of this breakdownChina: 433 citing papers, 4.8% of this breakdownBelgium: 373 citing papers, 4.2% of this breakdownSpain: 322 citing papers, 3.6% of this breakdownSwitzerland: 253 citing papers, 2.8% of this breakdownJapan: 221 citing papers, 2.5% of this breakdown
0%15.1%Other 28.9%

Institutions

Fields

  • Medicine77.9%
  • Immunology and Microbiology11.5%
  • Biochemistry, Genetics and Molecular Biology6.8%
  • Engineering0.9%
  • Neuroscience0.6%
  • Pharmacology, Toxicology and Pharmaceutics0.4%
  • Other1.9%

Topics

  • Spondyloarthritis Studies and Treatments19.7%
  • Rheumatoid Arthritis Research and Therapies17.2%
  • Psoriasis: Treatment and Pathogenesis9.9%
  • Autoimmune and Inflammatory Disorders Research6.3%
  • Spine and Intervertebral Disc Pathology2.9%
  • Systemic Lupus Erythematosus Research2.5%
  • Other41.5%

Coauthors

All papers

Open in search
  1. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

    Authors: Sofía Ramiro, Elena Nikiphorou, Alexandre Sepriano, Augusta Ortolan, Casper Webers, Xenofon Baraliakos, Robert Landewé, Filip Van den Bosch, B. Boteva, Ann Bremander, Philippe Carron, Adrian Ciurea, F. van Gaalen, Pál Géher, Lianne S. Gensler, Josef Hermann, Manouk de Hooge, Markéta Hušáková, Uta Kiltz, Clementina López‐Medina, Pedro Machado, Helena Marzo‐Ortega, Anna Moltó, Victoria Navarro‐Compán, Michael J. Nissen, Fernando Pimentel‐Santos, Denis Poddubnyy, Fabian Proft, Martín Rudwaleit, Mark Telkman, Sizheng Steven Zhao, Nelly Ziadé, Désirée van der Heijde - Annals of the Rheumatic Diseases 2022 cited by 929

  2. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update

    Authors: Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, Maarten de Wit, Iain McInnes, Maxime Dougados, Jette Primdahl, Dennis McGonagle, Daniel Aletaha, Andra Bălănescu, P Bálint, Heidi Bertheussen, Wolf‐­Henning Boehncke, Gerd R Burmester, Juan D Canete, Nemanja Damjanov, Tue Wenzel Kragstrup, Tore K. Kvien, Robert Landewé, Rik Lories, Helena Marzo‐Ortega, Denis Poddubnyy, Santiago Rodrigues-Manica, Georg Schett, Douglas J. Veale, Filip Van den Bosch, Désirée van der Heijde, Josef S Smolen - Annals of the Rheumatic Diseases 2020 cited by 948

  3. The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general

    Authors: Martín Rudwaleit, D. van der Heijde, R. B. M. Landewé, Nurullah Akkoç, J. Brandt, Chung‐Tei Chou, Maxime Dougados, Feng Huang, Jieruo Gu, Yeşim Kirazlı, Filip Van den Bosch, Ignazio Olivieri, Euthalia Roussou, Salvatore Scarpato, IJ Sørensen, Rafael Valle‐Oñate, Ulrich Weber, James Cheng‐Chung Wei, Joachim Sieper - Annals of the Rheumatic Diseases 2010 cited by 1,733

  4. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update

    Authors: Laure Gossec, Andreas Kerschbaumer, Ricardo J O Ferreira, Daniel Aletaha, Xenofon Baraliakos, Heidi Bertheussen, Wolf‐­Henning Boehncke, Bente Appel Esbensen, Iain B. McInnes, Dennis McGonagle, Kevin Winthrop, Andra Bălănescu, P Bálint, Gerd R Burmester, Juan D. Cañete, Pascal Claudepierre, Lihi Eder, Merete Lund Hetland, Annamaria Iagnocco, Lars Erik Kristensen, Rik Lories, Rubén Queiró, Daniele Mauro, Helena Marzo‐Ortega, Philip J. Mease, Peter Nash, Wendy Wagenaar, L. Savage, Georg Schett, Stephanie Shoop-Worrall, Yoshiya Tanaka, Filip Van den Bosch, Annette H M van der Helm–van Mil, Alen Zabotti, Désirée van der Heijde, Josef S Smolen - Annals of the Rheumatic Diseases 2024 cited by 331

  5. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial

    Authors: Gerd R Burmester, Joel M. Kremer, Filip Van den Bosch, Alan Kivitz, Louis Bessette, Yihan Li, Yijie Zhou, Mohamed I. A. Othman, Aileen L. Pangan, Heidi S. Camp - The Lancet 2018 cited by 397

  6. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force

    Authors: Josef S Smolen, Monika Schöls, Jürgen Braun, Maxime Dougados, Oliver FitzGerald, Dafna D. Gladman, Arthur Kavanaugh, Robert Landewé, Philip J. Mease, Joachim Sieper, Tanja Stamm, Maarten de Wit, Daniel Aletaha, Xenofon Baraliakos, Neil Betteridge, Filip Van den Bosch, Laura C. Coates, Paul Emery, Lianne S. Gensler, Laure Gossec, Philip Helliwell, Merryn Jongkees, Tore K Kvien, Robert D. Inman, Iain B. McInnes, Mara Maccarone, Pedro Machado, Anna Moltó, Alexis Ogdie, Denis Poddubnyy, Christopher T. Ritchlin, Martín Rudwaleit, Adrian Tanew, Bing Thio, Douglas J. Veale, Kurt de Vlam, Désirée van der Heijde - Annals of the Rheumatic Diseases 2017 cited by 676

  7. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

    Authors: Désirée van der Heijde, In-Ho Song, Aileen L. Pangan, Atul Deodhar, Filip Van den Bosch, Walter P. Maksymowych, Tae‐Hwan Kim, Mitsumasa Kishimoto, Andrea Everding, Yunxia Sui, Xin Wang, Alvina D. Chu, Joachim Sieper - The Lancet 2019 cited by 346

  8. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

    Authors: Peter Nash, Andreas Kerschbaumer, Thomas Dörner, Maxime Dougados, Roy Fleischmann, Klaus Geißler, Iain B. McInnes, Janet Pope, Désirée van der Heijde, Michaela Stoffer, Tsutomu Takeuchi, Michael Trauner, Kevin Winthrop, Maarten de Wit, Daniel Aletaha, Xenofon Baraliakos, Wolf‐­Henning Boehncke, Paul Emery, John D. Isaacs, Joel M. Kremer, Eun Bong Lee, Walter P. Maksymowych, Marieke Voshaar, Lai‐Shan Tam, Yoshiya Tanaka, Filip Van den Bosch, René Westhovens, Ricardo Machado Xavier, Josef S Smolen - Annals of the Rheumatic Diseases 2020 cited by 288

  9. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis

    Authors: Désirée van der Heijde, Sofía Ramiro, Robert Landewé, Xenofon Baraliakos, Filip Van den Bosch, Alexandre Sepriano, Andrea Regel, Adrian Ciurea, Hanne Dagfinrud, Maxime Dougados, F. van Gaalen, Pál Géher, Irene van der Horst‐Bruinsma, Robert D. Inman, Merryn Jongkees, Uta Kiltz, Tore K Kvien, Pedro Machado, Helena Marzo‐Ortega, Anna Moltó, Victoria Navarro‐Compán, Salih Özgöçmen, Fernando Pimentel‐Santos, John D. Reveille, Martín Rudwaleit, Jochen Sieper, Percival D. Sampaio‐Barros, Dieter Wiek, Jürgen Braun - Annals of the Rheumatic Diseases 2017 cited by 1,563

  10. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2

    Authors: Philip J. Mease, Apinya Lertratanakul, J. Anderson, Kim Papp, Filip Van den Bosch, Shigeyoshi Tsuji, Eva Dokoupilová, Mauro Waldemar Keiserman, Xin Wang, Sheng Zhong, R. Mccaskill, Patrick Zueger, Aileen L. Pangan, William Tillett - Annals of the Rheumatic Diseases 2020 cited by 233

  11. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Atul Deodhar, Filip Van den Bosch, Denis Poddubnyy, Walter P. Maksymowych, Désirée van der Heijde, Tae‐Hwan Kim, Mitsumasa Kishimoto, Ricardo Blanco, Yuanyuan Duan, Yihan Li, Aileen L. Pangan, Peter Wung, In‐Ho Song - The Lancet 2022 cited by 135

  12. EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis

    Authors: Alen Zabotti, Gabriele De Marco, Laure Gossec, Xenofon Baraliakos, Daniel Aletaha, Annamaria Iagnocco, Paolo Gisondi, P Bálint, Heidi Bertheussen, Wolf‐­Henning Boehncke, Nemanja Damjanov, Maarten de Wit, Enzo Errichetti, Helena Marzo‐Ortega, Mikhail Protopopov, L. Puig, Rubén Queiró, Piero Ruscitti, L. Savage, Georg Schett, Stefan Siebert, Tanja Stamm, Paul Studenic, Ilaria Tinazzi, Filip Van den Bosch, Annette H M van der Helm–van Mil, ‬‬‬‬Abdulla Watad, Josef S Smolen, Dennis McGonagle - Annals of the Rheumatic Diseases 2023 cited by 116

  13. MRI-based Synthetic CT in the Detection of Structural Lesions in Patients with Suspected Sacroiliitis: Comparison with MRI

    Authors: Lennart Jans, Min Chen, Dirk Elewaut, Filip Van den Bosch, Philippe Carron, Peggy Jacques, Ruth Wittoek, Jacob L. Jaremko, Nele Herregods - Radiology 2020 cited by 168

  14. MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group

    Authors: Walter P. Maksymowych, R. Lambert, Mikkel Østergaard, Susanne Juhl Pedersen, Pedro Machado, Ulrich Weber, Alexander N. Bennett, Juergen Braun, Rubén Burgos‐Vargas, Manouk de Hooge, Atul Deodhar, Iris Eshed, Anne Grethe Jurik, Kay‐Geert Hermann, Robert Landewé, Helena Marzo‐Ortega, Victoria Navarro‐Compán, Denis Poddubnyy, M. Reijnierse, Martín Rudwaleit, Joachim Sieper, Filip Van den Bosch, Désirée van der Heijde, Irene E. van der Horst‐Bruinsma, Stephanie Wichuk, Xenofon Baraliakos - Annals of the Rheumatic Diseases 2019 cited by 304

  15. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials

    Authors: Désirée van der Heijde, Atul Deodhar, Xenofon Baraliakos, Matthew Brown, Hiroaki Dobashi, Maxime Dougados, Dirk Elewaut, A.M. Ellis, C. Fleurinck, Karl Gaffney, Lianne S. Gensler, Nigil Haroon, Marina Magrey, Walter P. Maksymowych, Alexander Marten, Ute Massow, Marga Oortgiesen, Denis Poddubnyy, Martín Rudwaleit, Julie Shepherd‐Smith, Tetsuya Tomita, Filip Van den Bosch, T. Vaux, Huji Xu - Annals of the Rheumatic Diseases 2023 cited by 106

  16. Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group

    Authors: R. Lambert, P. Bakker, Désirée van der Heijde, Ulrich Weber, Martín Rudwaleit, Kay‐Geert Hermann, Joachim Sieper, Xenofon Baraliakos, A. N. Bennett, Jürgen Braun, Rubén Burgos‐Vargas, Maxime Dougados, Susanne Juhl Pedersen, Anne Grethe Jurik, Walter P. Maksymowych, Helena Marzo‐Ortega, Mikkel Østergaard, Denis Poddubnyy, M. Reijnierse, Filip Van den Bosch, Irene van der Horst‐Bruinsma, Robert Landewé - Annals of the Rheumatic Diseases 2016 cited by 528

  17. Brief Report: Dialister as a Microbial Marker of Disease Activity in Spondyloarthritis

    Authors: Raúl Y. Tito, Heleen Cypers, Marie Joossens, Gaëlle Varkas, Liesbet Van Praet, E Glorieus, Filip Van den Bosch, Martine De Vos, Jeroen Raes, Dirk Elewaut - Arthritis & Rheumatology 2016 cited by 274

  18. Revisiting the gut–joint axis: links between gut inflammation and spondyloarthritis

    Authors: Eric Gracey, Lars Vereecke, Dermot McGovern, Mareike Fröhling, Georg Schett, Silvio Danese, Martine De Vos, Filip Van den Bosch, Dirk Elewaut - Nature Reviews Rheumatology 2020 cited by 179

  19. Goodbye to the term ‘ankylosing spondylitis’, hello ‘axial spondyloarthritis’: time to embrace the ASAS-defined nomenclature

    Authors: Désirée van der Heijde, Anna Moltó, Sofía Ramiro, Jürgen Braun, Maxime Dougados, F. van Gaalen, Lianne S. Gensler, Robert D. Inman, Robert Landewé, Helena Marzo‐Ortega, Victoria Navarro‐Compán, Andri Phoka, Denis Poddubnyy, Mikhail Protopopov, John D. Reveille, Martín Rudwaleit, Percival D. Sampaio‐Barros, Alexandre Sepriano, Joachim Sieper, Filip Van den Bosch, Irene van der Horst‐Bruinsma, Pedro Machado, Xenofon Baraliakos - Annals of the Rheumatic Diseases 2023 cited by 104

  20. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis

    Authors: Désirée van der Heijde, E. Lie, Tore K Kvien, Joachim Sieper, Filip Van den Bosch, Joachim Listing, Joseph M. Braun, R. Landewé - Annals of the Rheumatic Diseases 2008 cited by 631

  21. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

    Authors: Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados, Philip J. Mease, Atul Deodhar, Walter P. Maksymowych, Filip Van den Bosch, Joachim Sieper, Tetsuya Tomita, Robert Landewé, Fangyi Zhao, Eswar Krishnan, David H. Adams, Beth A. Pangallo, Hilde Carlier, Melvin Churchill, Kathleen P. Flint, Geoffrey Gladstein, Maria Greenwald, Mary P. Howell, Akgun Ince, Jeffrey Kaine, Daksha Mehta, Eric Peters, Roel Querubin, John D. Reveille, Richard Roseff, Roger J. Diegel, Christine Thai, Louis Bessette, Frédéric Morin, Proton Rahman, Aaron Alejandro Barrera Rodriguez, Fidencio Cons-Molina, Sergio Duran Barragan, Cassandra M. Skinner, César Pacheco‐Tena, César Ramos-Remus, Juan Cruz Rizo Rodriguez, Seung-Jae Hong, Yeon-Ah Lee, Ji Hyeon Ju, Seong Wook Kang, Tae‐Hwan Kim, Chang Keun Lee, Eun Bong Lee, Sang Heon Lee, Min‐Chan Park, Kichul Shin, Sang‐Hoon Lee, Hung-An Chen, Ying‐Chou Chen, Song‐Chou Hsieh, Joung‐Liang Lan, Zdeněk Dvořák, Radka Moravcová, Martina Malcova, Yoshinori Taniguchi, Mitsumasa Kishimoto, Kurisu Tada, Hiroaki Dobashi, Kentaro Inui, Yukitaka Ueki, Yoshifuji Matsumoto, Yoshinobu Koyama, Kazuhiro Hatta, Tatsuya Atsumi, Midori Goto, Kiyoshi Matsui, Yuya Takakubo, Gunther Neeck, Denis Poddubnyy, Andrea Rubbert‐Roth, Malgorzata Szymańska, Tomasz Blicharski, Anna Dudek, Artur Racewicz, Rafał Wojciechowski, Marleen van de Sande, E. N. Griep, Mike Nurmohamed, Galina Matsievskaya, Е. Шмидт, Marina Stanislav, S. S. Yakushin, О. Б. Ершова, А. П. Ребров, Tibor Balázs, Regina Cseuz, Edit Drescher, Gyula Poór - The Lancet 2018 cited by 359

  22. RORγt inhibition selectively targets IL-17 producing iNKT and γδ-T cells enriched in Spondyloarthritis patients

    Authors: Koen Venken, Peggy Jacques, Céline Mortier, Mark E. Labadia, Tine Decruy, Julie Coudenys, Kathleen Hoyt, A. Wayne, Robert Hughes, Michael Turner, Sofie Van Gassen, Liesbet Martens, Dustin Smith, Christian Harcken, Joseph Wahle, Chao-Ting Wang, Eveline Verheugen, Nadia Schryvers, Gaëlle Varkas, Heleen Cypers, Ruth Wittoek, Yves Piette, Lieve Gyselbrecht, Serge Van Calenbergh, Filip Van den Bosch, Yvan Saeys, Gerald Nabozny, Dirk Elewaut - Nature Communications 2018 cited by 310

  23. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial

    Authors: Philip J. Mease, Laura C. Coates, Philip Helliwell, Mykola Stanislavchuk, Anna Rychlewska-Hańczewska, Anna Dudek, Walid Abi‐Saab, Chantal Tasset, Luc Meuleners, Pille Harrison, R. Besuyen, Annegret Van der Aa, Neelufar Mozaffarian, Joy M. Greer, Rebecca Kunder, Filip Van den Bosch, Dafna D. Gladman - The Lancet 2018 cited by 204

  24. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial

    Authors: Andrew J.K. Östör, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Gabriela Alperovich, Wenjing Lü, Zailong Wang, Ahmed M. Soliman, Ann Eldred, Lisa Barcomb, Alan Kivitz - Annals of the Rheumatic Diseases 2021 cited by 106